Home / Businesswire / SEQENS. A New Name for a Global Leader in Pharmaceutical Synthesis and Specialty Ingredients.

SEQENS. A New Name for a Global Leader in Pharmaceutical Synthesis and Specialty Ingredients.

LYON, France–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/APIs?src=hash" target="_blank"gt;#APIslt;/agt;–Novacap, a global player in the pharmaceutical synthesis and specialty
ingredients, with a broad portfolio of products and services and a wide
range of technologies, today announced that it will combine its Contract
Development and Manufacturing Organization subsidiaries – PCI Synthesis,
PCAS, Uetikon and Proteus – into a new entity to be known as SEQENS.

The name change is effective today but will be rolled out during Q1 2019
at each of SEQENS’ 24 manufacturing plants and 3 R&D centers in Europe,
North America and Asia. At that time, signage and websites will be
updated to reflect the new corporate entity.

The move positions SEQENS as an integrated global leader in
pharmaceutical synthesis and specialty ingredients, delivering
outstanding performance, unrivalled market responsiveness and
tailor-made solutions to its customers. By consolidating its service
offerings, SEQENS can better serve its customers with global access to
its 3,200 employees, including more than 300 scientists, engineers and
experts, and ensure that products are successfully transferred into
production.

SEQENS. Taking science to next level

SEQENS’ name refers naturally to the company’s core synthesis
activities, combined with the sequencing of molecules, competencies and
technologies to take science to the next level.

In the pharmaceutical industry, SEQENS supports its customers for the
development, scale-up and manufacturing of drug substances from
preclinical through to commercial phase and offers a large portfolio of
APIs and proprietary products.

SEQENS also develops custom solutions and ingredients for the most
demanding industries such as healthcare, electronics, cosmetics, food
and homecare.

SEQENS. The Continuum of Progress

“As SEQENS, we can better leverage our strong expertise to develop and
produce highly complex molecules with unique skills and the largest
continuum of technologies available on the market. I am proud of what we
have achieved so far, on behalf of SEQENS’ 3,200 scientists, engineers,
and experts working across a range of fields such as QHSE, industrial
methods and processes, quality, sales and marketing, finance,
innovation, legal and more,” says Pierre Luzeau, SEQENS CEO.

The management teams of PCI Synthesis, PCAS, Uetikon and Proteus will
remain in place, and continue to report to Pierre Luzeau, who previously
served as CEO of Novacap.

About SEQENS

SEQENS is an integrated global leader in pharmaceutical synthesis and
specialty ingredients.

With 24 manufacturing sites and 3 R&D centers in Europe, North America
and Asia, SEQENS develops custom solutions and ingredients for the most
demanding industries such as healthcare, electronics, cosmetics, food
and homecare.

Driven by a culture of excellence and a strong entrepreneurial spirit,
SEQENS’ 3,200 employees are committed to providing its customers with
the highest level of service and product quality while acting ethically
in the frame of its Corporate Social Responsibility program.

More information on www.seqens.com

Contacts

Linda Pendergast-Savage
Birnbach Communications
508-224-7905
[email protected]